PPIDT00292
Drug Information
| Name | Ixekizumab |
|---|---|
| Sequence | QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG |
| DrugBank_ID | DB11569 |
| Type | biotech |
| Indication | Ixekizumab is indicated for the treatment of patients aged six years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also indicated in adult patients with active psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis with objective signs of inflammation.[L40953] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | — |
|
| Injection, solution | — |
80 mg/1ml
|
| Injection, solution | Parenteral; Subcutaneous |
80 MG
|
| Injection, solution | Subcutaneous |
20 mg/0.25mL
|
| Injection, solution | Subcutaneous |
40 mg/0.5mL
|
| Injection, solution | Subcutaneous |
80 mg/1mL
|
| Solution | Subcutaneous |
80 mg / mL
|
| Solution | Subcutaneous |
80.000 mg
|
| Solution | Subcutaneous |
8000000 mg
|
| Injection, solution | Subcutaneous |
80 mg
|
| Injection, solution | Subcutaneous |
80 mg/ml
|
| Injection, solution | — |
80 mg/ml
|